Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials
Purpose: The aim of this meta-analysis is to compare the clinical efficacy and safety of baloxavir with other anti-influenza agents or placebo in the treatment of influenza. Methods: PubMed, Embase, Web of Science, Google Scholar, Scopus, CINAHL, Cochrane databases and clinical registration were sea...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-10-01
|
| Series: | Journal of Microbiology, Immunology and Infection |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S168411822100092X |
| _version_ | 1818355750161874944 |
|---|---|
| author | Yu-Chi Kuo Chih-Cheng Lai Ya-Hui Wang Chao-Hsien Chen Cheng-Yi Wang |
| author_facet | Yu-Chi Kuo Chih-Cheng Lai Ya-Hui Wang Chao-Hsien Chen Cheng-Yi Wang |
| author_sort | Yu-Chi Kuo |
| collection | DOAJ |
| description | Purpose: The aim of this meta-analysis is to compare the clinical efficacy and safety of baloxavir with other anti-influenza agents or placebo in the treatment of influenza. Methods: PubMed, Embase, Web of Science, Google Scholar, Scopus, CINAHL, Cochrane databases and clinical registration were searched from inception until February 15 2021 for relevant randomized controlled trials (RCTs). Only phase 3 RCTs evaluating the usefulness of baloxavir in the treatment of influenza were included. Results: Three RCTs enrolling 3771 patients (baloxavir group, n = 1451; oseltamivir group, n = 1288; placebo group, n = 1032) were included. Compared with oseltamivir, baloxavir had an insignificantly shorter time to the alleviation of symptoms (mean difference [MD], −1.29 h; 95% CI, −6.80 to 4.21; I2 = 0%). In contrast, baloxavir had a significantly shorter time to the alleviation of symptoms than placebo (MD, −26.32 h; 95% CI, −33.78 to −18.86; I2 = 0%). Baloxavir was associated with a significant decline in influenza virus titers and viral RNA load compared to oseltamivir and placebo. Baloxavir was associated with a lower risk of any adverse events than oseltamivir (OR, 0.82; 95% CI, 0.69–0.98; I2 = 0%) and placebo (OR, 0.79; 95% CI, 0.66–0.96; I2 = 0%). Conclusions: The findings of this meta-analysis suggested that baloxavir is superior to placebo in the treatment of influenza in both clinical outcome and virological response. Moreover, baloxavir was found to have a better virological response than oseltamivir and to be as effective as oseltamivir clinically. Compared with oseltamivir and placebo, baloxavir appears to be a relatively safe anti-influenza agent. |
| first_indexed | 2024-12-13T19:46:17Z |
| format | Article |
| id | doaj.art-a9d11ff673a34603a1e9e7c6739099ce |
| institution | Directory Open Access Journal |
| issn | 1684-1182 |
| language | English |
| last_indexed | 2024-12-13T19:46:17Z |
| publishDate | 2021-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Microbiology, Immunology and Infection |
| spelling | doaj.art-a9d11ff673a34603a1e9e7c6739099ce2022-12-21T23:33:33ZengElsevierJournal of Microbiology, Immunology and Infection1684-11822021-10-01545865875Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trialsYu-Chi Kuo0Chih-Cheng Lai1Ya-Hui Wang2Chao-Hsien Chen3Cheng-Yi Wang4Department of Internal Medicine, Chi-Mei Hospital, Chiali, Tainan, TaiwanDepartment of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan, TaiwanMedical Research Center, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan; Corresponding author. Medical Research Center, Cardinal Tien Hospital, No.362, Zhongzheng Road, Xindian Dist., New Taipei, 231, Taiwan.Division of Pulmonary, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan; Department of Medicine, MacKay Medical College, New Taipei, Taiwan; Corresponding author. Division of Pulmonary, Department of Internal Medicine, MacKay Memorial Hospital, No. 45, Minsheng Rd., Tamsui District, New Taipei, 251, Taiwan.Department of Internal Medicine, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan; Corresponding author. Department of Internal Medicine, Cardinal Tien Hospital, No.362, Zhongzheng Road, Xindian Dist., New Taipei, 231, Taiwan.Purpose: The aim of this meta-analysis is to compare the clinical efficacy and safety of baloxavir with other anti-influenza agents or placebo in the treatment of influenza. Methods: PubMed, Embase, Web of Science, Google Scholar, Scopus, CINAHL, Cochrane databases and clinical registration were searched from inception until February 15 2021 for relevant randomized controlled trials (RCTs). Only phase 3 RCTs evaluating the usefulness of baloxavir in the treatment of influenza were included. Results: Three RCTs enrolling 3771 patients (baloxavir group, n = 1451; oseltamivir group, n = 1288; placebo group, n = 1032) were included. Compared with oseltamivir, baloxavir had an insignificantly shorter time to the alleviation of symptoms (mean difference [MD], −1.29 h; 95% CI, −6.80 to 4.21; I2 = 0%). In contrast, baloxavir had a significantly shorter time to the alleviation of symptoms than placebo (MD, −26.32 h; 95% CI, −33.78 to −18.86; I2 = 0%). Baloxavir was associated with a significant decline in influenza virus titers and viral RNA load compared to oseltamivir and placebo. Baloxavir was associated with a lower risk of any adverse events than oseltamivir (OR, 0.82; 95% CI, 0.69–0.98; I2 = 0%) and placebo (OR, 0.79; 95% CI, 0.66–0.96; I2 = 0%). Conclusions: The findings of this meta-analysis suggested that baloxavir is superior to placebo in the treatment of influenza in both clinical outcome and virological response. Moreover, baloxavir was found to have a better virological response than oseltamivir and to be as effective as oseltamivir clinically. Compared with oseltamivir and placebo, baloxavir appears to be a relatively safe anti-influenza agent.http://www.sciencedirect.com/science/article/pii/S168411822100092XBaloxavirInfluenzaOseltamivir |
| spellingShingle | Yu-Chi Kuo Chih-Cheng Lai Ya-Hui Wang Chao-Hsien Chen Cheng-Yi Wang Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials Journal of Microbiology, Immunology and Infection Baloxavir Influenza Oseltamivir |
| title | Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials |
| title_full | Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials |
| title_fullStr | Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials |
| title_full_unstemmed | Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials |
| title_short | Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials |
| title_sort | clinical efficacy and safety of baloxavir marboxil in the treatment of influenza a systematic review and meta analysis of randomized controlled trials |
| topic | Baloxavir Influenza Oseltamivir |
| url | http://www.sciencedirect.com/science/article/pii/S168411822100092X |
| work_keys_str_mv | AT yuchikuo clinicalefficacyandsafetyofbaloxavirmarboxilinthetreatmentofinfluenzaasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT chihchenglai clinicalefficacyandsafetyofbaloxavirmarboxilinthetreatmentofinfluenzaasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT yahuiwang clinicalefficacyandsafetyofbaloxavirmarboxilinthetreatmentofinfluenzaasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT chaohsienchen clinicalefficacyandsafetyofbaloxavirmarboxilinthetreatmentofinfluenzaasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT chengyiwang clinicalefficacyandsafetyofbaloxavirmarboxilinthetreatmentofinfluenzaasystematicreviewandmetaanalysisofrandomizedcontrolledtrials |